Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Health & MedicineOne-Off3y
Manifold MarketsNo KYCVerified resolution dataFairly calibratedCurrent community forecastYes 78.9%
Forecasters
29
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 8 hours ago
StaleJan 26, 24, 12:13 AM UTCJan 1, 30, 7:59 AM UTC
Trends
Rules
In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy.
- Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).
- To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein).
- The gene therapy must be for humans.
- Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?
